Nutriband Secures $2 Million Line of Credit Financing Facility to be Used for Commercialization of AVERSA(TM) Abuse-Deterrent Transdermal Technology

Author's Avatar
Mar 28, 2023

ORLANDO, FL / ACCESSWIRE / March 28, 2023 / Nutriband Inc. ("Company") (NASDAQ:NTRB)(NASDAQ:NTRBW) has entered into a three-year $2,000,000 Credit Line facility to provide financing through the FDA approval process into commercial scale manufacturing for the Company's patented lead product, AVERSAâ„¢ Fentanyl, an abuse-deterrent fentanyl transdermal system. AVERSAâ„¢ Fentanyl contains Nutriband's proprietary transdermal abuse deterrent technology.